Dietary Supplement
Diindolylmethane (DIM)
Total Trials
3
Max Phase
—
Type
DIETARY SUPPLEMENT
Molecule
—
Success Metrics
Completion Rate
0%(0/2)
Active Trials
0(0%)
Terminated
2(67%)
Phase Distribution
Ph not_applicable
1
33%
Ph phase_1
1
33%
Ph early_phase_1
1
33%
Phase Distribution
2
Early Stage
0
Mid Stage
0
Late Stage
Phase Distribution3 total trials
Early Phase 1First-in-human
1(33.3%)
Phase 1Safety & dosage
1(33.3%)
N/ANon-phased studies
1(33.3%)
Highest Phase Reached
Phase 1Trial Status & Enrollment
Completion Rate
0.0%
0 of 2 finished
Non-Completion Rate
100.0%
2 ended early
Currently Active
0
trials recruiting
Total Trials
3
all time
Status Distribution
Terminated(2)
Other(1)
Detailed Status
Terminated2
unknown1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
0
Success Rate
0.0%
Most Advanced
Early Phase 1
Trials by Phase
Early Phase 11 (33.3%)
Phase 11 (33.3%)
N/A1 (33.3%)
Trials by Status
terminated267%
unknown133%
Recent Activity
0 active trials
Showing 3 of 3
terminatednot_applicable
New Therapy of Laryngeal Papilloma In Children
NCT00591305
terminatedearly_phase_1
DIM as a Treatment for Thyroid Disease
NCT01846364
unknownphase_1
The Potential for Oral Diindolylmethane (DIM) Supplementation to Increase the Production of the BRCA1 Protein in BRCA1 Mutation Carriers
NCT01022333
Clinical Trials (3)
Showing 3 of 3 trials
NCT00591305Not Applicable
New Therapy of Laryngeal Papilloma In Children
NCT01846364Early Phase 1
DIM as a Treatment for Thyroid Disease
NCT01022333Phase 1
The Potential for Oral Diindolylmethane (DIM) Supplementation to Increase the Production of the BRCA1 Protein in BRCA1 Mutation Carriers
All 3 trials loaded
Drug Details
- Intervention Type
- DIETARY SUPPLEMENT
- Total Trials
- 3